Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants

C. R. Reis, A. M. van der Sloot, A. Natoni, E. Szegezdi, R. Setroikromo, M. Meijer, K. Sjollema, F. Stricher, R. H. Cool, A. Samali, L. Serrano, W. J. Quax*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

56 Citations (Scopus)
221 Downloads (Pure)

Abstract

The tumour necrosis factor family member TNF-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in a variety of cancer cells through the activation of death receptors 4 (DR4) and 5 (DR5) and is considered a promising anticancer therapeutic agent. As apoptosis seems to occur primarily via only one of the two death receptors in many cancer cells, the introduction of DR selectivity is thought to create more potent TRAIL agonists with superior therapeutic properties. By use of a computer-aided structure-based design followed by rational combination of mutations, we obtained variants that signal exclusively via DR4. Besides an enhanced selectivity, these TRAIL-DR4 agonists show superior affinity to DR4, and a high apoptosis-inducing activity against several TRAIL-sensitive and -resistant cancer cell lines in vitro. Intriguingly, combined treatment of the DR4-selective variant and a DR5-selective TRAIL variant in cancer cell lines signalling by both death receptors leads to a significant increase in activity when compared with wild-type rhTRAIL or each single rhTRAIL variant. Our results suggest that TRAIL induced apoptosis via high-affinity and rapid-selective homotrimerization of each DR represent an important step towards an efficient cancer treatment.

Original languageEnglish
Article number83
Number of pages10
JournalCell death & disease
Volume1
DOIs
Publication statusPublished - 21-Oct-2010

Keywords

  • apoptosis
  • TRAIL
  • death receptors
  • homotrimerization
  • FADD-DEPENDENT APOPTOSIS
  • NF-KAPPA-B
  • LIGAND TRAIL
  • SELECTIVE MUTANTS
  • DECOY RECEPTORS
  • DR5
  • APO2L/TRAIL
  • CASPASE-8
  • DOMAIN
  • INHIBITION

Cite this